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Abstract: The central nervous system (CNS) innate immune response includes an arsenal of molecules and receptors expressed by pro-
fessional phagocytes, glial cells and neurons that is involved in host defence and clearance of toxic and dangerous cell debris. However, 
any uncontrolled innate immune responses within the CNS are widely recognized as playing a major role in the development of autoim-
mune disorders and neurodegeneration, with multiple sclerosis (MS) Alzheimer's disease (AD) being primary examples. Hence, it is im-
portant to identify the key regulatory mechanisms involved in the control of CNS innate immunity and which could be harnessed to ex-
plore novel therapeutic avenues. Neuroimmune regulatory proteins (NIReg) such as CD95L, CD200, CD47, sialic acid, complement 
regulatory proteins (CD55, CD46, fH, C3a), HMGB1, may control the adverse immune responses in health and diseases. In the absence 
of these regulators, when neurons die by apoptosis, become infected or damaged, microglia and infiltrating immune cells are free to cause 
injury as well as an adverse inflammatory response in acute and chronic settings. We will herein provide new emphasis on the role of the 
pair CD200-CD200R in MS and its experimental models: experimental autoimmune encephalomyelitis (EAE) and Theiler’s virus in-
duced demyelinating disease (TMEV-IDD). The interest of the cannabinoid system as inhibitor of inflammation prompt us to introduce
our findings about the role of endocannabinoids (eCBs) in promoting CD200-CD200 receptor (CD200R) interaction and the benefits 
caused in TMEV-IDD. Finally, we also review the current data on CD200-CD200R interaction in AD, as well as, in the aging brain.
Keywords: Neuroinflammation, microglia, neurons, neuroimmunoregulatory molecules, CD200, CD200R, multiple sclerosis, aging brain, 
Alzheimer’s disease, cannabinoids. 
INTRODUCTION 
 Immune cells classically involved in innate responses include 
natural killer cells, neutrophils, dendritic cells and macrophages 
that participate in the selective recognition and the clearance of 
pathogens and toxic cell debris during infection or tissue injury [1, 
2]. Nevertheless, these peripheral cells show little immunosurveil-
lance of the brain, and it is now evident that resident cells, glial 
cells, ependymal cells and even neurons are capable of mounting 
innate immune responses on their own [3]. The local innate immune 
response is based on the recognition of non-self and altered self- 
patterns by molecules and receptors expressed by microglia but also 
present on astrocytes, oligodendrocytes and neurons [4, 5]. The 
outcome of these interactions is dependent on the microenviron-
ment, as well as, on the nature of the ligands and on the nature and 
combination of the ligated receptors. From a therapeutic point of 
view, it is important to manipulate this innate immune response to 
promote clearance of pathogens or toxic proteins accumulated dur-
ing brain injury or in central nervous system (CNS) diseases [5, 6]. 
However, several innate immune molecules can contribute to cyto-
toxic and cytolitic activities and must be controlled to avoid neu-
ronal loss and excessive inflammation [7]. There is new emphasis 
on the role of neuroimmune regulatory proteins (NIRegs) involved 
in silencing and reshaping an adverse innate immune response such 
as, CD47 and CD200 expressed by neurons as “don’t eat me” sig-
nals that inhibit microglial activity preventing host cell attack, be-
sides to modulate microglial function and phenotype in situations of 
harmful and excessive inflammation [8]. Here, we present a review 
about CNS immunity and the modulation of CD200 and its receptor 
in multiple sclerosis (MS) and in the aging brain and Alzheimer’s  
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disease (AD). We show original data on the effects of an inhibitor 
of endocannabinoids (eCBs) uptake in the regulation of CD200-
CD200 receptor (CD200R) interaction in an experimental model of 
MS. 
CNS INNATE IMMUNE RESPONSE IN THE RESTORA-
TION OF BRAIN HOMEOSTASIS: ROLE OF MICRO-
GLIAL CELLS  
 Microglia constitute the highly versatile resident macrophages 
in the CNS, comprising 5% to 20% of the total glial cell population 
[9]. As reviewed by Yang et al., [10], in 1919, Ramón y Cajal’s 
disciple, Pío del Río-Hortega recognised microglial cells as a dif-
ferent cell type from the other glial cells. He also characterised 
microglial transformation from a ramified phenotype into ameboid 
phagocytic macrophage-like cells in the stab wounds made in ani-
mal brains [11]. From these observations, del Río-Hortega con-
cluded that microglia originated from peripheral mononuclear cells 
[11].  
 Interestingly, and after a long debate in which even the exis-
tence of microglial cells was questioned [12], microglia has finally 
been established as a distinct glial cell population from a myelo-
monocity origin [13]. Recently, it has been demonstrated that mi-
croglial cells are originated from a distinct myeloid precursor that 
migrates from the haematopoietic islands in the yolk sac to the de-
veloping brain parenchyma at embryonic day 8.5 [14]. 
 Microglia are widely distributed in the adult CNS, but differ-
ences in their cellular density among different brain areas have been 
reported in mice [9, 15] and humans [16]. Thus, microglial cells are 
more abundant in the telencephalon than in the diencephalon or the 
mesencephalon, with the rhombencephalon containing the lowest 
amount of these cells [9, 17]. Not only there is an uneven distribu-
tion of microglia across the cerebral anatomical regions but be-
tween the grey and white matter (the latter containing higher mi-
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croglial cell density than the former). Moreover, cumulative data 
show that microglial expression of tissue macrophage markers var-
ies within the different brain regions, as well as, their response to 
different stimuli [18, 19, 20].  
 In the adult healthy brain, microglia has been described to be in 
“resting” or “quiescent” state with a ramified morphology. How-
ever, this term has limitations and can lead to the misleading idea 
that microglia are dormant cells awaiting a signal that will wake 
them up. On the contrary, recent elegant in vivo imaging experi-
ments show “resting” microglia as highly dynamic cells, continu-
ously branching thin processes that survey and sample their micro-
environment [21, 22] in search for potential threats and danger sig-
nals. Thanks to this routine immunosurveillance of the CNS, mi-
croglia will remove apoptotic bodies and other potentially toxic 
cellular debris (myelin debris, amyloid deposits, protein aggregates, 
etc) [23, 24, 25]. In order to accomplish this task, it is essential that 
microglial cells are capable of distinguishing between “self” and 
“nonself” signals (Fig. 1). Clearence of pathogens and toxic cell 
debris during infection or tissue damage is based on the recognition 
of “nonself” and “altered-self” patterns by microglia, but also astro-
cytes, oligodendrocytes and neurons have been shown to be able to 
recognise those patterns [1, 4]. According to Medzhitov and Jane-
way [1], there is a plethora of the so-called “eat-me” signals ex-
pressed by pathogens and apoptotic or necrotic cells. Some of these 
signals are a heterogeneous group of molecules known as pathogen-
associated molecular patterns (PAMPs) and are characterised by 
being highly conserved through evolution with little antigenic vari-
ability [22]. These PAMPs are constituents of the microbial struc-
ture which induce in the host a strong innate immune reaction di-
rected towards the removal of the pathogen by phagocytosis [26]. 
The classical example of a PAMP is the lippopolysaccharide (LPS), 
component of the Gram negative external membrane. Analogous to 
PAMPS, it has been proposed that cells undergoing programmed 
cell death express de novo apoptotic cell-associated molecular pat-
terns (ACAMPs) [22, 27, 28]. These ACAMPs would play a key 
role in the embryonic process in which whole cell populations need 
to be cleared out without mounting an inflammatory response and 
minimising the presence of cellular debris [29]. Some ACAMPs 
include oxidized low density proteins, alteration of the membrane 
electrical charges, nucleic acids and phosphatydilserine [4, 30]. 
Similarly, damaged or stressed tissues release/express the so-called 
danger-associated molecular patterns (DAMPs). Some DAMPs 
including heat shock proteins (HSP), adenosine, ATP, high motility 
group box chromosomal protein 1 (HMGB-1), galectins and thiore-
doxin present adjuvant and pro-inflammatory activity [31]. Phago-
cytic cells recognise these PAMPs, ACAMPs and/or DAMPs, 
which can be either membrane-bound or soluble, through their pat-
tern recognition receptors (PRRs) [22, 28, 32]. Some of the PPRs 
include toll-like receptors (TLR), scavenger and manose receptors, 
CD14, CD36, complement receptors, phosphatydilserine receptor 
(PSR) and milk fat globulin (MFG-EGF8) [8]. Therefore, the acti-
vation of microglia, rather than an unspecific process, is highly 
dependent on the stimulus that originated it.  
 In contrast to this plethora of signals that might elicit an innate 
immune activation directed to the elimination of the pathogen, the 
apoptotic cell or the tissue debris; there is a complex set of interac-
tions that silence and reshape microglial response [1]. For instance, 
electrically active neurons inhibit the interferon- (IFN)-induced 
increase in major histocompatibility complex (MHC) class II ex-
pression in microglia [33]. Some neurotransmitters have modula-
Fig. (1). Roles of “eat me” and “don’t eat me” signals in the CNS innate immune responses. Scheme showing how microglial cells differenciate “self” 
from “non-self” cues.  
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tory effects on microglial response whereas others, like substance P 
enhance the activation of microglia [34]. Neurotrophins secreted by 
healthy neurons such as nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF) and to a lower extent neurotrophin-3 
(NT-3) were able to reverse the induction of MHC class II mole-
cules in microglia [35]. Interestingly, neurons express membrane-
bound molecules and/or secrete soluble mediators that function as 
“don’t eat me” signals, reshaping microglial response and inhibiting 
their phagocytic activity on the site of injury [4, 36]. These signals 
were originally grouped in a family of heterogeneous molecules 
called self-associated molecular patterns (SAMPs). It was sug-
gested that these SAMPs could interact with novel inhibitory PPRs, 
negatively modulating the innate immune response and promoting 
tissue repair [4]. These SAMPs signals are present in almost all host 
“normal-self” cells but not in pathogens and they are downregulated 
in apoptotic/necrotic cells (altered self). Thus, this “normal-self” 
identity can be lost. An example of a molecular marker of “normal-
self” is the presence of sialic acid in the terminal of glycoproteins 
and glycolipids, which can interact with different microglial recep-
tors [37]. One of these inhibitory receptors belongs to a family 
known as siglecs [38]. Siglecs contain immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) in their cytoplasmic tail which 
downregulate phagocytosis in macrophages and microglia [39, 40]. 
Most microorganisms lack sialic acid in their glycolipids and/or 
glycoproteins and in some cases, virally infected or transformed 
cells can show a deficient pattern of sialization, which is a strong 
signal of “altered-self” to promote phagocytosis. Also in apoptotic 
cells, a reduced expression of sialic acid has been shown [22].  
 Of particular interest is the physical interaction (by means of 
their membrane-bound proteins) between neurons and microglia. 
Thus, a group of SAMPs were renamed NIRegs to highlight their 
role in modulating, reshaping an adverse immune response and 
skewing microglia towards a protective phenotype. Interestingly, 
many of these NIRegs contain an ITIM domain in their cytoplasmic 
tails which negatively regulated microglial response to insults. 
 As mentioned before, siglecs are members of a subgroup of the 
immunoglobulins (Ig) superfamily that recognize the sialic acid 
residues on the periphery of cell surface glycolipids and glycopro-
tein. Siglecs contain an ITIM domain in their cytoplasmic tails 
which signal via the recruitment of tyrosine phosphatases such as 
SHP1 [40]. In this sense, when microglial siglecs interact with the 
neuronal glycocalix, neurotoxicity is alleviated [41].  
 Another interesting NIReg protein is the pair CD200- CD200R. 
CD200 is a 41-47 KDa protein belonging to the Ig supergene family 
characterised by two immunoglobulins superfamily (IgSF) domains 
[42, 43]. This surface protein is highly conserved and within the 
CNS is mainly expressed by neurons and vascular endothelium [42, 
44, 45, 46], but CD200 is present in almost peripheral cell types, 
thymocytes [47], T and B cells [43], dendritic cells [48] and even in 
brain astrocytes and oligodendrocytes [49, 50]. In contrast, 
CD200R, which also contains two IgSF domains and a longer cyto-
plasmic tail with an ITIM domain as showed in (Fig. 2) [42], is 
chiefly expressed by myeloid cells and microglia [46, 51]. How-
ever, CD200R has been described to be present also in thymocytes 
[52] as well as in T and B cells [43, 53]. Functional studies about 
the role of CD200-CD200R interaction within the brain indicate 
that this pair of molecules plays a critical role in neuronal protec-
tion in the setting of inflammatory-mediated neurodegeneration 
(Fig. 3). In particular, this immune-regulatory system, when defi-
cient, may contribute to chronic inflammation in MS, AD or in the 
aging brain as we will show in this review. Deletion of CD200 re-
sults in myeloid cells dysregulation and enhanced susceptibility to 
autoimmune response [51, 54].  
 Other neuron-microglia ligand-receptor interaction that can 
modulate microglial responsiveness is the neuronal CD47 (also  
Fig. (2). Binding of CD200-CD200R in the CNS. Scheme showing the 
binding of CD200 expressed in neurons, oligodendrocytes astrocytes and 
brain endothelial cells with its receptor CD200R expressed mainly in micro-
glial cells. Both molecules are type-1 membrane glycoprotein that belong to 
the IgSF and contain two IgSF domains. CD200R has a short intra-
cytoplasmic domain allowing the inhibitory signal to microglial cells. 
CD200 is expressed in a variety of lymphoid and non-lymphoid cells while 
CD200R is primarily expressed by myeloid cells (macrophages, monocytes 
and microglia). 
expressed by endothelium, astrocytes and dendritic cells) [55] and 
the microglial signal regulatory protein SIRP (CD172 ) which 
contains three extracellular Ig domains [56]. CD47-CD172  inter-
action recruits the tyrosine phosphatases SHP-1 and SHP-2 with 
inhibition of phagocytosis and synthesis of the anti-inflammatory 
cytokine TGF- [22]. Another NIReg with a potential critical role 
in neuroprotection include the pair neuronal CX3CL1 and micro-
glial CX3CR1 [57]. 
 Interestingly, some membrane receptors contain immunorecep-
tor tyrosine-based activation motifs (ITAM). ITAM-containing 
signalling adaptor proteins are associated with receptor subunits. 
After ligand-receptor interaction, tyrosine residues of the ITAMs 
become phosphorylated by members of the Src kinase family and 
subsequently serve as docking sites for Src homology 2 (SH2) do-
mains of Syk protein kinases which then mediate cellular activation 
via a number of downstream cascades [40]. Triggering receptor 
expressed on myeloid cells 2 (TREM-2) is an innate immune gly-
coprotein heterogeneously expressed in brain microglia [58]. It 
belongs to the immunoglobulin and lectin-like superfamily with a 
short cytoplasmic tail [59]. Interaction of TREM-2 with its unchar-
acterized ligand induces its association with the ITAM-containing 
adaptor molecule DAP12 followed by the recruitment of ZAP70, 
SYK, PI3K and phospholipase C [60]. Activation of TREM-
2/DAP12 leads to augmented phagocytosis with reduced expression 
of tumor necrosis factor- (TNF), interleukin (IL)-6 and inducible 
nitric oxide synthase (iNOS) [61]. Mutation of either TREM2 or 
DAP12 proteins lead to the rare Nasu-Hakola disease (NHD), also 
known as polycystic lipomembranous osteodysplasia with scleros- 
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ing leukoencephalopathy (PLOSL), an autosomal recessive inher-
ited disease [62]. While NHD patients carrying TREM-2 mutation 
present an early onset presenile dementia followed by delayed bone 
symptoms [63], patients with mutations in DAP12 display an early 
onset combination of presenile dementia and systemic bone cysts 
[64]. Interestingly, Piccio et al., [65, 66] showed that a soluble form 
of TREM-2 was present in the cerebrospinal fluid (CSF) of patients 
with MS and that blockade of TREM-2 with a blocking antibody 
exacerbated experimental autoimmune encephalomyelitis (EAE) in 
rodents. These observations suggest a crucial role of TREM-2 in 
preventing neurodegenerative processes. So far the nature of the 
TREM-2 ligand remains unknown. It has been suggested that 
TREM-2 bind anionic ligands of the surface of Gram positive and 
Gram negative bacteria, including Neisseria gonorrheae, as well as 
an unidentified ligand in the astrocytoma cell line HTB12 [61]. 
Importantly, Hsieh et al. [67], using a TREM2/Fc chimera, showed 
that neurons undergoing apoptosis increased the expression of a 
TREM-2 ligand (TREM-2L), inducing their phagocytosis by BV2 
cells (a murine microglia cell line). This effect could be reversed 
with the use of a blocking antibody against microglial TREM-2 
[67]. 
 This review will examine how the CNS innate immune re-
sponse maintains a critical balance between protective and poten-
tially harmful effects by the interaction of CD200 and its receptor 
CD200R in neurological diseases which involve neuroinflammation 
with special emphasis to MS, AD and aging brain. The balance 
between the destructive and protective effects of the innate immune 
response must be precisely regulated in order to promote conditions 
that support brain repair and re-established tissue homeostasis. 
MULTIPLE SCLEROSIS 
 MS belongs to a larger group of inflammatory demyelinating 
diseases of the CNS which include besides the different manifesta-
tions of MS, acute disseminated leukoencephalitis, Devic’s neuro-
myelitis optica and Balo’s concentric sclerosis. Although these 
diseases differ in clinical course, imaging pathology and im-
munopathogenesis, they share some essential structural features of 
their lesions, as they all occur on a background of inflammatory 
reaction composed of lymphocytes, activated macrophages and 
microglia and show demyelination. MS is a chronic inflammatory 
and neurodegenerative disease affecting over 2.5 million individu-
als worldwide. The pathological hallmark of MS is white matter 
demyelination but there are other features such as axonal and neu-
ronal damage, grey matter demyelination, composition of vascular 
cuffs (monocytes, T cells, B cells, plasma cells), loss of oligoden-
drocytes and anatomical lesions that vary between patients [68]. 
The pathogenesis of MS is still not fully understood, although sig-
nificant progress has been made in the last decades [69]. Several 
immunological abnormalities have been identified in patients with 
MS, such as the presence of oligoclonal bands in the CSF, higher 
levels of T cell activation and decrease of regulatory T cell func-
tion. The presence of inflammation driven by the adaptive immune 
system in absence of infectious pathogens, the response to immu-
nomodulatory therapy, in addition to the association with human 
leukocyte antigen (HLA) and the predominance for young women 
strongly suggest an autoimmune origin. Regarding the susceptibil-
ity for suffering MS, familial and twin studies have revealed a con-
cordance in monozygous twin of 30% compared with dyzogous 
twin and sibling of 2-5%. The identification of genomic factors 
predisposing for MS have revealed the association with HLA class 
II and specifically with the HLA-DRB1*1501 allele. In respect to 
environmental factors, several factors have been validated by dif-
ferent studies and meta-analysis including the association with 
common infections (Epstein-Barr virus, Herpesvirus type 6 and MS 
retrovirus), levels of vitamin D and sun exposition [70,71]. Regard-
ing association with infections, the picture is complex because no 
single pathogen has been linked with MS in a clear way. Therapies 
that have been developed so far are aimed at multiple mechanisms 
such as broad immune suppression or inhibition of immune cell 
migration. Some of these therapies reduce the clinical disease activ-
ity and the progression of lesion load as determined by magnetic 
resonance imaging (MRI), but so far no therapy is available that can 
cure MS or even halt its progression. The search for more effective 
approaches is therefore necessary. 
Macrophages and Microglia as Cell Players in MS 
 The activation of macrophages and microglia is critical in the 
development and expansion of MS lesions [72, 73] as clusters of 
activated microglia are observed before demyelination [74]. 
Moreover, infiltrated macrophages and activated microglia are the 
predominant cell types present in expanding MS lesions [75], and 
are involved in myelin phagocytosis [76]. In that way in order to 
halt the progression of MS one should particularly target the cells of 
myeloid origin to dampen neuroinflammation and demyelination.  
 Other types of macrophages located at the interface of the CNS 
and the peripheral immune system are the perivascular, meningeal 
and choroid plexus macrophages. The perivascular macrophages 
found in the Virchow-Robin space between the endothelial vessel 
lining and the glia limitants have been involved in scavenging of 
pathogens and other substances derived from the CNS or the circu-
Fig. (3). Neuron-microglia crosstalk. A) In control conditions the crosstalk between neuron-microglia via the CD200-CD200R interaction is working cor-
rectly. The inhibitory signal is contributing to the maintenance of brain homeostasis and immune privilege. B) In inflammatory situations the crosstalk be-
tween neuron-microglia through the CD200-CD200R interaction is altered. The reduced inhibitory input from CD200 causes a disturbed equilibrium which 
results in activation of microglia and neuronal damage in MS, in the aging brain and AD. 
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lation as well as antigen presentation [77]. Moreover, these cells 
also act as gate keepers, as they facilitate the migration of leuko-
cytes from the perivascular space to the neuropile [78]. Perivascular 
macrophages increased numbers in the CNS of MS patients, and in 
experimental models of MS, like EAE and Theiler’s murine en-
cephalomyelitits virus-induced demyelinating disease (TMEV-
IDD). Since perivascular macrophages increased expression of 
adhesion molecules and chemokines, these cells are most likely 
involved in attracting circulating leukocytes in MS. Whether peri-
vascular macrophages themselves remain at their location or also 
invade the brain parenchyma or how these cells contribute to MS is 
still unclear. Depending on the activation signals macro-phages can 
turn on a classical or alternative activation program [79, 80]. IFN
and LPS produce a classical activation of macrophages termed M1 
and involve mitogen activated protein kinase (MAPKs) signaling 
pathways [81]. M1 cells are pro-inflammatory and express high 
levels of nitric oxide (NO), cytokines like TNF, IL-1, IL-6, IL-12, 
IL-23 and opsonin (Fc) and the complement type 3 (CR3) recep-
tors. These last receptors are required for antibody or complement 
mediated phagocytosis. In addition, M1 macrophages can promote 
T helper 1 (Th1) responses [82]. 
 By contrast, IL-4, IL-13, TGF- or glucocorticoids induce al-
ternatively activated macrophages (M2) [79]. It has been suggested 
that the phenotype of M2 cells involves the downregulation of nu-
clear factor NF-B and signal transducer and activator of transcrip-
tion (STAT-1) [82]. Importantly, M2 cells express high amounts of 
IL-10 and the mannose receptor possibly to mediate scavenging of 
debris, tissue remodeling and repair. The M1/M2 distinction should 
not necessarily invoke a concept of a cellular differentiation state, 
but as a spectrum of pro- versus anti-inflammatory responses, rep-
resenting as a continuum between these two extreme activation 
states.  
 In the case of microglia, depending on the type of activation, 
microglial cells can proliferate, lose their ramifications and can 
induce the expression of neurotrophic factors or pro- or anti-
inflammatory cytokines [79, 83]. During neuroinflammation, acti-
vation of microglia is initiated through the MAPKs pathways simi-
lar to M1 macrophages [84, 85] and upregulate MHC class II mole-
cules and secrete inflammatory mediators like NO, IL-1, IL-6 and 
TNF. The upregulation of surface receptors like FC and C3 allow 
microglia to participate in antibody and complement-mediated 
phagocytosis [86]. In active MS lesions macrophages act mainly in 
a pro-inflammatory way corresponding with phenotype M1. How-
ever, it has been described that foamy macrophages swich their 
phenotype and start to express markers of M2 phenotype [87]. This 
change probably contributes to gliosis formation by astrocytes. 
Microglia also is able to display reactions associated with both 
protective and deleterious effects in the CNS [18]. It is therefore 
likely that microglia activation may be polarized depending on 
activation signal. This has been shown in mice [6] but evidence in 
humans is still lacking. The cause of classical activation of macro-
phages and microglia in MS is still subject of debate in terms of 
questions about if this activation is followed by, or a consequence 
of T cell activation, oligodendrocyte apoptosis or other pathological 
events. Once activated, the role of macrophages and microglia in 
MS has been shown to mediate both beneficial and detrimental 
effects. By efficiently removing myelin and cellular debris macro-
phages facilitate remyelination [88] being the cells positive for the 
receptor of the chemokines CCL3 and CCL5, CCR5+, the subpopu-
lation of macrophages involved in this process [89]. Although bene-
ficial effects of activated macrophages/microglia in MS are evident, 
these effects are only to occur after initial damage which is attrib-
uted to the activated macrophages as well. In fact, macrophages and 
microglia are key players in lesion initiation and development, and 
therefore in disease progression. Clusters of microglia were present 
in the MS brain even before cellular infiltrates or demyelination 
was visible [90]. This first observation was confirmed in various 
studies and has been linked to the earliest stages of lesion develop-
ment [74, 91]. Macrophages and microglia predominate in expand-
ing MS lesions and greatly outnumber lymphocytes [75] localizing 
in close proximity to damaged axons [92]. Phagocytosis of myelin 
seems to occur by a common mechanism mediated by complement 
and immunoglobulin deposition [93]. Macrophages and microglia 
furthermore secrete many inflammatory cytokines, reactive oxygen 
species (ROS) and chemokines [84] enhancing inflammation. A 
disproportional activation of macrophages/ microglia can be a key 
event in triggering a cascade of events that eventually leads to mul-
tiple demyelinated areas in the CNS. In that way, treatments that 
interfere with the activation of these cells would be a good ap-
proach to halt lesion development and further disease progression. 
IMMUNOREGULATORY MOLECULES IN NEUROIN-
FLAMMATION 
 As commented before, in the CNS exists several intrinsic 
mechanisms that tightly regulate the activities of microglia [94]. 
This is critical, as an uncontrolled inflammatory reaction could be 
detrimental to a tissue that is known for its poor regenerating capac-
ity. Quiescent microglia inspect and guard their environment [95], 
but when a certain threshold is exceeded they become activated and 
show retraction of ramifications acquiring round phenotype and 
upregulate a number a markers like CD45 and MHC class II. These 
cells will become motile, phagocytic and might display local prolif-
eration [96]. A proper balance in immune activating and immune 
inhibitory signals thus regulates their activation. It has been postu-
lated that excessive microglia/macrophage activation in a patho-
logical setting is due to imbalanced control, reflected by impaired 
immune activation, immune inhibition or both, and could lead to 
disease progression as seen in MS [97]. This view subsequently 
implies that correcting the equilibrium by supplying extra inhibitory 
signals specific for these cells may dampen the pathological in-
flammatory response and restore the immune suppressed environ-
ment of the CNS [8]. A specific therapeutic candidate target to 
diminish inflammation in MS via the immune inhibitory molecules 
is CD200 and its receptor CD200R.  
CD200-CD200R in MS  
 CD200 is a membrane glycoprotein belonging to the IgSF, with 
CNS expression extremely high. Among other cells, neurons ex-
press the highest level of CD200 [46]. CD200 has a short cytoplas-
mic tail with no known signaling motifs, then CD200 itself exerts 
functions in the cell on which it is expressed its receptor. Precisely, 
CD200R, homologous to CD200, is expressed mainly on myeloid 
cells such as macrophages, microglia and dendritic cells [98, 99] 
and on a subset of B and T cells [53, 100]. CD200R has a cyto-
plasmic tail which contains three tyrosine residues, one of which 
forms part of an NPXY motif. Upon binding to its ligand, the tyro-
sine residues become phosphorylated, and adaptor proteins down-
stream of tyrosine kinase (DOK) 1 and 2 are recruited. This ulti-
mately leads to inhibition of the MAPK p38, extracellular kinase 
(ERK) and c-Jun terminal kinase (JNK), the common pathways 
involved in classical activation of macrophages and microglia. This 
in turn results in inhibition of release of pro-inflammatory cytokines 
like IL-1, IL-6 and TNF [101, 102], but promote the secretion of 
IL-10 [103]. This is an important point as CD200R engagement not 
only decreases the production of pro-inflammatory cytokines, but 
enhances the production of an anti-inflammatory cytokine. There-
fore, through CD200-CD200R interaction, the activity of macro-
phages and microglia can be down-regulated. Interestingly, using 
neuron-microglial cell co-cultures model, as described by Hernán-
gomez et al. [103], IL-10 protected neurons from microglia-induced 
cytotoxicity. In this context, it has been suggested that CD200-
CD200R interaction may be one of the mechanisms by which IL-10 
protects neurons from inflammatory damage by increasing the ex-
pression of CD200 in neurons [103]. In fact, in time-lapse experi-
ments using co-cultures of neurons-microglial BV2 cells activated 
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with LPS/IFN, the addition of the anti-inflammatory cytokines IL-
4 and IL-10 rescue neurons from inflammation induce death while 
the blockade of the interaction of CD200 with its receptor enhanced 
neuronal death induced by the inflammatory stimuli (Fig. 4).
 The high expression of CD200 in the CNS is thought to be a 
mechanism of constitutive immune suppression and is developmen-
tally regulated in the mouse brain (104). In fact, the blockade of 
CD200-CD200R interaction, for instance, in CD200-/- deficient 
mice, leads to spontaneous activation and increased proliferation of 
microglia and macrophages, demonstrated by upregulation of CD45 
which is a hallmark of microglial activation and expression of 
iNOS [51]. In CD200 deficient mice induction of EAE and experi-
mental uveoretinitis showed enhanced macrophage infiltration and 
a more rapid and severe disease course compared to wild type mice 
[51, 105]. 
 A blocking antibody against CD200R aggravated EAE in rats 
by enhancing infiltration of T cells and activated macrophages 
[106]. In addition, the interruption of CD200-CD200R interaction 
increased neuronal death in macrophage/microglia co-cultures [103, 
106]. These findings implicate that CD200 is a potent immune in-
hibitory molecule and that reduced inhibitory input from CD200 
causes a disturbed equilibrium which subsequently results in cellu-
lar activation and tissue damage. This has been confirmed in MS, 
since the decreased expression of CD200 and other immune inhibi-
tory molecules like CD47 in chronic active lesions was accompa-
nied of macrophage/microglia activation expanding the lesions 
[97]. A reduction of CD200 and CD200R gene expression in the 
spinal cord was also observed at later chronic phases in the viral 
model of MS, TMEV-IDD [103]. Immune inhibition might be 
hampered in MS and this could facilitate the activated state of 
macrophages/microglia with demyelinating activity as a conse-
quence. Importantly, findings in animal studies show that increased 
CD200R signaling can be beneficial. For example, mice that have 
inherently elevated levels of CD200 show ameliorated disease signs 
in the EAE model accompanied by enhanced neuroprotection and 
elevated levels of IL-10 [49]. As expected, these animals displayed 
fewer activated macrophages/microglia and less demyelination and 
axonal damage. CD200R is likely to mediate several actions of 
alternatively activated macrophages (M2) such as the reduced se-
cretion of pro-inflammatory cytokines. Moreover, CD200R expres-
sion on T cells seemed to be restricted to Th2 cells [107]. In sum-
mary, impaired immune inhibition by reduced CD200/CD200R 
interaction might result in a pro-inflammatory environment that 
may contribute to demyelination and axonal injury in MS. 
THE CANNABINOID SYSTEM: CANNABINOID RECEP-
TORS AND ENDOCANNABINOIDS PRODUCTION AND 
INACTIVATION 
 Cannabinoids (CBs) activate mainly the cloned CB1 and CB2 
receptors, but also can interact with the TRPV1 vanilloid receptor, 
GPR55 and other yet uncloned receptors such as abn-CBD recep-
tors [108, 109]. In addition, CBs can interact with peroxisome pro-
liferator-activated receptors, PPAR  and PPAR [110, 111]. CB1 
receptors are expressed abundantly throughout the brain by many 
neurons, as well as outside the CNS, but at much lower levels [112, 
113, 114]. CB1 receptors are Gi/o protein-coupled receptors that 
modulate the activity of several plasma membrane proteins and 
intracellular signaling pathways. Several studies suggest that short-
term versus long-term activation of CB1 receptors affects different 
cellular functions. For example, activation of neuronal CB1 recep-
Fig. (4). Microglia-neurons co-cultures: The anti-inflammatory cytokines, IL-4 and IL-10, reduce neuronal death- induced by inflammatory stimuli 
while the impairment of CD200-CD200R interaction enhanced neuronal death. A) Representative time-lapse experiment of BV2 microglial cells/neurons 
subjected to LPS (10 ng/ml)/IFN (100U) stimulation for 24 h. The addition of IL-4 (10 ng/ml) or IL-10 (10 ng/ml) reduced neuronal death while the impair-
ment of CD200-CD200R interaction using a blocker of CD200, CD200 blocking antibody (5g/mL), augmented neuronal death as reflected in quantification 
experiments B, and C respectively. Quantification data show the mean ± SEM from four independent experiments. Statistics: B, *p<0.05 vs control; #p<0.05 
vs LPS/IFN; ##p<0.01 vs LPS/IFN; C, *p<0.05 vs LPS/IFN; ##p<0.01 vs LPS/IFN.
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tors for seconds inhibits presynaptic N-type calcium channels and 
activates inwardly rectifying potassium channels, reducing neuro-
transmission [115, 116]. In contrast, CB1 receptor activation for 
minutes to hours changes gene expression, for example, inducing 
the expression of neuroprotective proteins, such as BDNF, known 
to counteract cell damage [117]. Under neuropathological condi-
tions whereby the blood-brain barrier (BBB) is disrupted, large 
quantities of leukocytes enter the CNS and participate in neuroin-
flammatory responses. Leukocytes express CB1 receptors, although 
at lower levels compared with neurons, and their activation modu-
lates related immune responses [118]. Thus, CBs may affect neu-
roinflammation through their action at CB1 receptors expressed by 
invading leukocytes. CB2 receptors are also Gi/o protein-coupled 
receptors [119]. They share 44% protein identity with CB1 recep-
tors and display a distinct pharmacological profile and expression 
pattern. Many laboratories reported that CB2 receptors are not ex-
pressed in healthy brain [118, 119, 120] suggesting that they are not 
expressed by healthy neurons, astrocytes, resting microglial cells, 
and oligodendrocytes. However, more recent studies show that 
microglia, astrocytes, oligodendrocytes, progenitor neural cells and 
even neurons can express CB2 receptors [121, 122, 123]. However, 
CB2 receptors are expressed primarily by immune cells [118]. 9-
Tetrahydrocannabinol (THC) binds to CB2 receptors as a partial 
agonist [119, 124], an effect that leads to reduced inflammation by 
inducing apoptosis of immune cells [125] and inhibiting the ability 
of macrophages to process antigens and prime helper T cells [126, 
127]. The expression and pharmacological dichotomy between CB2 
and CB1 receptors have tremendous pharmaceutical potential, as 
compounds that interact selectively with CB2 receptors may pro-
vide anti-inflammatory drugs devoid of CB1-induced psychoactive 
adverse effects. 
 In 1992, Mechoulam and coworkers identified the first endoge-
nous compound that binds CB1 receptors with high affinity [128]. 
This compound, arachidonoylethanolamide (AEA), which was 
named anandamide, is produced in an activity-dependent manner, 
activates CB receptors, and is inactivated enzymatically. The activ-
ity-dependent increase in AEA production was initially demon-
strated with neurons in primary culture and then, with mi-
crodialysates from freely moving rats [129, 130, 131]. This re-
sponse requires a rise in intracellular calcium, which increases the 
activity of an acyltransferase specific for the precursor of AEA, N-
arachidonoylphosphatidylethanolamide (NAPE), and a NAPE-
specific phospholipase D, generating AEA (Fig. 5). In 1995, two 
laboratories identified a second endogenous ligand, 2-
arachidonoylglycerol (2-AG) which is approximately 200 times 
more abundant than AEA in brain and activates CB1 and CB2 re-
ceptors [120, 132]. Neurons and glial cells produce and inactivate 
2-AG [129, 131, 133, 134]. Its production also requires sustained 
increase in intracellular calcium levels and the activation of the 
phospholipase C-diacylglycerol lipase pathway [135, 136]. Several 
lipids structurally related to AEA and 2-AG can also interact with 
CB receptors, among them, palmitoylethanolamide (PEA) which 
contains a 16:0 fatty acid moiety may be a subtype of eCB. PEA is 
produced and inactivated by cells and induced biological effects 
that are blocked by a CB2 antagonist although it does not bind to 
any known CB receptors [131, 137, 138, 139]. The bioactivity of 
eCBs can be terminated by desensitization and internalization of 
CB receptors, clearance of eCBs from the extracellular milieu and 
Fig. (5). Models showing AEA and 2-AG production and inactivation. AEA is produced by phospholipase D hydrolysing NAPE which is produced by N-
acyltransferase. AEA is released toward the extracellular space and activates CB1, CB2 and TRPV1 receptors; AEA is hydrolysed by fatty acid amide hydro-
lase (FAAH) into arachidonic acid plus ethanolamine. 2-AG is produced by diacylglycerol lipase (DGL) hydrolysing diacylglycerol (DAG) which is produced 
by phosphatidylinositol-specific phospholipase C. 2-AG is released toward the extracellular space and activates CB1 and CB2 receptors, hydrolysed by 
monoacylglycerol lipase (MGL) into arachidonic acid plus glycerol. 
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by enzymatic hydrolysis of eCBs, namely AEA by fatty acid amide 
hydrolase (FAAH) and 2-AG by monoacylglycerol lipase (MGL), 
ABH serine hydrolase and cyclooxigenase 2 [140, 141, 142, 143]. 
The characteristics of AEA and 2-AG uptake into cells are similar 
and suggest a common mechanism [135]. However, whether a pro-
tein mediates this uptake is still controversial. In summary, the eCB 
family consists of several structurally related lipids that interact 
with CB receptors. Several studies have identified eCBs as retro-
grade signaling molecules, being generated in a calcium-dependent 
manner from postsynaptic terminals, diffusing toward presynaptic 
terminals and inhibiting neurotransmitter release [144, 145, 146]. 
Figure 6 shows the current signaling relationship between glia and 
neurons and the role played by eCBs.  
Macrophages/Microglia as Targets of Anti-inflammatory Ac-
tions of CBs in MS Models 
 None of the currently available or experimental therapies are 
specifically aimed at halt the function of macrophages/microglia. 
Most therapeutic targets originally developed in EAE were aimed at 
limiting T cell activities and migration. Although T cells are re-
quired in the induction phase of EAE their critical role in MS is still 
elusive [147]. Using a CD200R agonistic compound like the fusion 
protein CD200 Fc in MS could suppress macrophage/microglia 
activation, restore the intrinsic immune suppressed environment of 
the CNS and may thereby restrain disease activity. We here propose 
to focus on the role of eCBs and exogenous CBs in the regulation of 
macrophages/microglia function and their effects in MS and its 
experimental models. 
  Extracts from the cannabis plant have been used medicinally 
for thousands of years, but it is only within the last two decades that 
our understanding of cannabinoid physiology and the evidence for 
therapeutic benefit of cannabinoids has begun to accumulate. Here, 
we will provide the advances in our understanding of eCB system 
(eCS), and how cannabinoids may help in the management of MS 
and its experimental models. Recent observations are beginning to 
suggest positive effects of cannabinoids in neuroinflammatory dis-
eases like MS, with evidence of anti-inflammation, encouragement 
of remyelination and neuroprotection. Clinical trial studies have 
demonstrated the benefit of CBs in alleviating MS-related symp-
toms [148, 149]. Exogenous administration of CBs has also been 
shown to be beneficial in several animal models of MS [150, 151, 
152, 153, 154]. CBs have anti-inflammatory and neuroprotective 
activities as well as promote oligodendrocyte survival [121, 155]. 
 Cumulative evidence has established that there is a dynamic 
interplay between the eCS, the immune system and the CNS [156, 
157]. Studies on the role played by the eCS during neuroinflamma-
tion support the interest of this system as a novel target for pharma-
cological therapy [153, 158, 159, 160]. In the TMEV-IDD model, 
exogenous CB agonists attenuated the pathological features of the 
disease [151, 152]. This effect was also observed when the endoge-
nous levels of the eCB AEA are elevated by pharmacological inter-
vention [161-163]. Microglial cells are possible targets for immu-
nomodulatory activities of eCBs, a hypothesis that is supported by 
the presence of cannabinoid receptors and the enzymes responsible 
for their synthesis and degradation [122, 164-166]. The endogenous 
ligands AEA and 2-AG are also synthesized by microglial cells 
which produce approximately 20-fold more eCBs than neurons and 
astrocytes [166]. The eCS is highly activated during brain inflam-
mation and AEA has been shown to be increased in active lesions 
of MS patients, to protect neurons from inflammatory damage [167, 
168]. 
Fig. (6). Current signalling relationship between glia and neurons related to cannabinoids. A sustained elevation in intracellular calcium leads to in-
creased eCBs production. At postsynaptic neurons eCBs production increases when metabotropic glutamate receptors and voltage-sensitive calcium channels 
are activated. In microglia and astrocytes, eCB production increases when purinergic P2X7 receptors are activated or when LPS or proinflammatory cytokines 
are acting in these glial cells. CB1 receptors are abundantly expressed on pre-synaptic terminals and inhibit neurotransmitter release. Astrocytes also express 
CB1 receptors at lower levels than neurons and their activation regulate energy metabolism and cell survival. Activated microglial cells express mainly CB2 
receptors that inhibit cytokines and inflammatory mediators.  
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eCBs Promote CD-200-CD200R Interaction 
 eCS has arisen as a promising new therapeutic target for the 
treatment of MS [153, 158, 169]. In animal models of MS, exoge-
nous CB agonists alleviate disease symptomatology [150-152], a 
benefit also produced by pharmacological interventions aimed at 
increasing the levels of eCBs [159, 161, 162, 170]. Uncontrolled 
innate immune responses within the CNS are widely recognized as 
playing a major role in the development of autoimmune disorders 
and neurodegeneration, with MS and AD being primary examples. 
However, the role of the eCS in the regulation of inhibitory im-
munoregulatory proteins and their impact in microglial function has 
not been completely elucidated. During the past years, several in 
vitro and in vivo studies have suggested that eCS participates in the 
control of brain immune responses as well as in the protection of 
the CNS against injury [171]. During immune-mediated attack of 
the brain, it has been hypothesized that the activation of eCBs rep-
resents a protective mechanism, aimed at reducing both neurode-
generative and inflammatory damage through various and partially 
converging mechanisms that involve neuronal and immune cells. 
The major eCBs, AEA and 2-AG, have been shown to exert neuro-
protective activity largely thought to be mediated through two spe-
cific CB receptors, the CB1 and CB2 receptors. Regarding innate 
immunity and in particular, CD200-CD200R, recently, our lab 
showed that the treatment with AEA induced the recovery of 
CD200 and CD200R gene expression that was reduced in the 
TMEV model of MS [103]. This was accompanied by decreased 
inflammatory mediators and reduced microglial reactivity. Here, in 
an attempt to further support the ability of AEA to modulate the 
interaction of CD200 with its receptor, we show that the administra-
tion of an inhibitor of AEA uptake (UCM-707) to TMEV-infected 
mice also induced a significant recovery in the expression levels of 
CD200 (Fig. 7A; p<0.05) that was decreased in TMEV-diseased 
mice. Treatment with UCM-707 did not significantly modify the 
expression of CD200R mRNA (Fig. 7B), although there was a trend 
toward increase. The effects of UCM-707 on CD200 mRNA were 
accompanied by a diminished expression of IL-1 mRNA (Fig. 7D;
p<0.05) and an increased of IL-10 mRNA expression (Fig. 7C;
p<0.05). Therefore, increased AEA tone [162] prevented gene ex-
pression of a pro-inflammatory cytokine such as IL-1 and in-
creased the expression of the anti-inflammatory cytokine IL-10, 
accordingly with a reduction in microglial reactivity, likely by in-
creasing CD200 expression in the spinal cord. Importantly, the 
axonal damage observed in TMEV-infected mice in comparison to 
Sham animals (p<0.01) was reduced after treatment with UCM-707 
(p<0.05) as evaluated by SMI32 staining (Fig. 7E). Analyses of 
motor function in TMEV-infected mice treated with UCM-707 
confirmed previous data from our group [162], as vertical (p<0.05) 
and horizontal activity (p<0.001) deficits were ameliorated (Fig. 
7F). These data indicate that CD200 negatively correlates with the 
degree of spinal cord axonal damage induced by TMEV and sug-
gest that increased CD200 expression may be one of the mecha-
nisms contributing to the anti-inflammatory effect observed in the 
TMEV-IDD model of MS by enhancing eCB tone [161, 162]. 
 The mechanisms that lead to reduction of damage and to pro-
mote repair involve switching macrophage functional activation to 
include decreased pro-inflammatory cytokines [79]. In studies from 
our lab we have described that macrophages infected with TMEV 
increased their production of AEA and that both, AEA and inhibi-
tors of AEA cellular re-uptake inhibited IL-12p40 release [161]. 
The identification of microglia as one of the major sources of IL-23 
in brain sections from MS patients points out the importance of 
microglial cells as cellular targets to down-regulate this family of 
heterodimeric cytokines. In the TMEV-IDD model of MS, it is 
unknown whether TMEV-infected microglia exhibit the autocrine 
regulatory mechanism between IL-10 and the cytokines of IL-12 
family [172] but data from our lab have established the molecular 
mechanisms by which AEA might regulate the IL-12p70/IL-23 axis 
and IL-10 in TMEV-infected microglial cells and in the TMEV-
IDD model of MS [173, 174].  
 Taken together, our findings support the hypothesis that en-
hancing endogenous anti-inflammatory regulatory systems like the 
eCS, basic mechanisms of innate immunity like CD200-CD200R 
interaction that are disrupted in chronic inflammatory diseases such 
as, MS can be restored representing a new therapeutic strategy that 
prevents harmful inflammation and axonal damage [175, 176].  
REGULATION OF MICROGLIAL ACTIVATION BY 
CD200-CD200R INTERACTION IN OTHER NEUROIN-
FLAMMATORY CONTEXT: ALZHEIMER’S DISEASE 
AND THE AGING BRAIN 
 The role of inflammation in AD has been intensively studied 
[177, 178]. Pathological studies of AD indicated the presence of 
activated microglia, reactive astrocytes and complement activation 
on association with amyloid  (A) containing plaques, suggesting 
that a kind of chronic inflammation was ongoing [179, 180]. A 
range of in vitro studies using cultured microglia from humans and 
rodents indicated that aggregated A peptide activates microglia to 
a pro-inflammatory state capable to produce a wide range of neuro-
toxic mediators [181, 182, 183]. In this line, anti-inflammatory 
therapies have been considered for treating this disease [184]. Be-
cause clinical trials with anti-inflammatory compounds did not 
generally show effectiveness at slowing the progression of AD, new 
inflammatory therapeutic targets are needed. These would include 
the enhancing of the function of endogenous immune regulatory 
molecules such as CD200 and its CD200R.  
CD200 and CD200R in Human Elderly Brain and in AD 
 Recent studies have focused in the characterization of CD200 
and CD200R expression in elderly human brains, as well as in AD. 
One of these studies showed a decrease in CD200 mRNA expres-
sion in the hippocampus of rats with increasing age [50], in agree-
ment with those observed in MS lesions [97]. The main findings 
obtained from brain tissues affected by AD showed that there is a 
deficit of CD200 but also of CD200R [181]. As confirmed in other 
studies CD200 is abundant in the human brain while CD200R is 
expressed at lower levels [46]. In fact, low expression of CD200R 
by microglia was confirmed at the mRNA and protein levels using 
cultured human microglia compared to blood-derived macrophages 
[181]. Neuronal expression of CD200 was decreased in brain re-
gions affected by AD pathology evaluated by quantitative meas-
urements of protein and mRNA in brain extracts as well as in anti-
body stained tissue sections. Interestingly, in the normal human 
brain differences in CD200 immunoreactivity can be observed de-
pending on the brain area studied, while in AD brain the main de-
creases of CD200 labeling correspond to the hippocampus and infe-
rior temporal gyrus. In agreement with previous data obtained from 
C57/BL6 mice [49] not only neurons but also astrocytes were posi-
tive for CD200 labeling in the human brains [181]. CD200R mRNA 
expression was also reduced in AD brains, specifically in regions 
affected by the pathology in comparison with matched no disease 
brains. In LPS models of neuroinflammation a decreased expression 
of CD200R has been described within the brain [185]. In the case of 
MS, no changes in CD200R were observed in brain lesions from 
MS patients [97], but in the experimental model of MS, TMEV-
IDD a decreased expression of CD200 mRNA was observed at 
chronic phases of the disease [103]. It is suggested that a deficiency 
of CD200 in AD brain could contribute to maintaining chronic 
inflammation as has been hypothesized in MS, but also a deficiency 
in CD200R provokes a reduced efficiency of the CD200-CD200R 
complex to limit or control inflammation and therefore, the CD200-
CD200R interaction in elderly brain might not be functioning in a 
correct way. Previous studies showed that the inhibitory response to 
CD200 is dependent on the level of expression of CD200R in re-
sponding cells [101]. Increasing the expression of CD200 and 
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Fig. (7). The inhibitor of AEA uptake, UCM-707, induces a recovery in the expression of CD200 mRNA in the spinal cord of TMEV-IDD mice. TMEV-
infected mice were subjected at 60 days pi (during established disease) to the administration of the selective inhibitor of AEA uptake, UCM-707 (5 mg/kg) for 
12 consecutive days. A) Level of expression of CD200 mRNA, evaluated by real time-PCR, in Sham mice and TMEV-infected mice subjected to UCM-707 or 
vehicle administration. TMEV-infected mice show downregulation of CD200 mRNA expression (p<0.05) compared to Sham animals. UCM-707 treatment 
significantly increased the expression of CD200 in the spinal cord of TMEV-infected mice (p<0.05). B) Levels of expression of CD200R mRNA, evaluated by 
real time-PCR, in Sham mice and TMEV-infected mice subjected to UCM-707 or vehicle administration. No significant changes in the level of CD200R ex-
pression were found among the different groups. UCM-707 treatment did not modify the level of CD200R expression. C) Expression of IL-1 mRNA, evalu-
ated by real time-PCR, in Sham mice and in TMEV-infected mice subjected to UCM-707 treatment or vehicle administration. TMEV-infected mice show ele-
vated levels of IL-1 (p<0.01) vs Sham mice in the spinal cord. UCM-707 treatment significantly down-regulates IL-1 expression (p<0.05). D) Expression of 
IL-10 mRNA, evaluated by real time-PCR, in Sham mice and TMEV-infected mice subjected to UCM-707 or vehicle administration. TMEV-infected mice 
show decreased level of expression of IL-10 in the spinal cord (P<0.05) vs Sham mice. UCM-707 treatment significantly up-regulates IL-10 expression in the 
spinal cord of TMEV-infected mice (P<0.05). E) Representative images of coronal spinal cord sections derived from Sham or TMEV-infected mice subjected 
or not to UCM-707 treatment stained with SMI32 for labelling axonal damage. The quantification of the images analysis shows that TMEV-infected mice 
present axonal degeneration (p<0.01) and UCM-707 treatment reduces axonal damage (p<0.05). Scale bars: 100 m. F) Activity cage performance: horizontal 
activity (left panel), vertical activity (right panel). TMEV-infected mice display decreased horizontal (P<0.001) and vertical activity (P<0.05) vs Sham mice. 
UCM-707 treatment significantly improves motor activity of TMEV-infected mice (p< 0.001 for horizontal activity and p<0.05 for vertical activity). Mice were 
assessed one day after the end of the 12-day treatment protocol. All values in A, B, C, E and F represent mean ± SEM from 7-8 mice per group.
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CD200R might provide a way of enhancing the efficiency of the 
system relevant from a therapeutic point of view [186]. Thus, the 
treatment with the CD200 fusion protein (CD200 Fc) was able to 
decrease microglial activation in the hippocampus of aged rats 
[187] and CD200 immunoadhesin diminished in a murine model of 
rheumatoid arthritis [188]. In this way, anti-inflammatory cytokines 
play a relevant role in regulating CD200-CD200R axis as IL-4 has 
been described to increase the expression of CD200 protein in neu-
ronal cultures from rodents and IL-4-/- mice had lower levels of 
CD200 in the brain [189]. Similarly, IL-10 has been recently shown 
that augmented the expression of CD200 in neurons [103]. Addi-
tional studies revealed that the expression of CD200R was also 
strongly increased by IL-4 in microglia and macrophages and IL-
13, that share common receptors with IL-4, exert a positive effect in 
increasing the expression of CD200R [181, 190]. In agreement with 
the above findings a significant age-related decline of IL-4 has been 
observed in the hippocampus of rats between 4 months and 22 
months which correlated with increased levels of IL-1 [191]. In 
summary, the above reports suggest that the impairment of CD200-
CD200R interaction may initiate a disturbed equilibrium in micro-
glia–neuron interaction, in the way of sensitizing the pro-
inflammatory reactivity of microglia and resulting in CNS injures 
or in the maintenance of chronic inflammatory states such as ob-
served in AD and in the aging brain. 
CONCLUSION AND FUTURE RESEARCH 
 The CNS innate immune response maintains a critical balance 
between the protective and potentially harmful effects of activating 
the innate immune system in CNS pathologies like MS and AD, as 
well as, in the aging brain that loss its homeostatic capacity with the 
consequent augmentation of morbidity and mortality. The balance 
between the protective and the deleterious effects of the innate im-
mune response must be tightly regulated to favor conditions that 
support brain repair and the return to tissue homeostasis. The 
CD200/CD200R inhibitory immune ligand-receptors system consti-
tutes one of the most suitable endogenous immunoregulatory mole-
cule candidate to restore the immune suppressive status of the CNS 
altered in chronic neuroinflammatory situations. The elucidation of 
the immunoregulatory pathways shared between the CNS innate 
immune system and microglial cells and their crosstalk with neu-
rons, oligodendrocytes and cells of the immune compartment repre-
sents an important challenge, but one that is of great therapeutic 
potential in preventing damage caused by macrophages/microglia in 
neuroinflammatory and neurodegenerative disorders. 
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ABBREVIATIONS 
2-AG = 2-Arachidonoyl glycerol 
Abn-CBD = Abnormal cannabidiol 
ACAMPs = Apoptotic cell-associated molecular patterns 
AD = Alzheimer`s disease 
AEA = Anandamide 
ATP = Adenosin Triposphate 
BBB = Blood-brain barrier 
BDNF = Brain-derived growth factor 
C3a = marker of complement activation 
CBs = Cannabinoids 
CB1 = Cannabinoid receptor 1 
CB2 = Cannabinoid receptor 2 
CD200 = ligand of CD200R 
CD200R = CD200 receptor 
CNS = Central nervous system 
CSF = Cerebrospinal fluid 
DAMPs = Danger-associated molecular patterns 
DOK = Downstream of tyrosine kinase 
EAE = Experimental autoimmune encephalomyelitis 
eCBs = Endocannabinoids 
eCS = Endocannabinoid system 
ERK = Extracellular receptor kinase 
FAAH = Fatty acid amide hydrolase 
Fc = Opsonin 
fH = factor H 
GPR = G-protein receptors 
HLA = Human leukocyte antigen 
HMGB-1 = High motility group box chromosomal pro-
tein1 
HSP = Heat shock protein 
IFN = Interferon 
Ig = Immunoglobulin 
IL = Interleukin 
iNOS = Inducible nitric oxide synthase 
ITAMs = Immunoreceptor tyrosine-based activation 
motifs 
ITIMs = Immunoreceptor tyrosine-based inhibitory 
motifs 
JNK = c-Jun N-terminal kinase 
LPS = Lipopolysaccharide 
M1 = Macrophage type 1 
M2 = Macrophage type 2 
MAPK = Mitogen activated protein kinase 
MFG-EGF 8 = Milk fat globulin 
MGL = Monoacylglycerol lipase 
MHC class II = Major histocompatibility complex class II 
MRI = Magnetic resonance imaging 
MS = Multiple Sclerosis 
NAPE = N-arachidonoylphosphatidylethanolamide 
NGF = Nerve growth factor 
NHD = Nasu-Hakola disease  
NIRegs = Neuroimmune regulatory proteins 
NO = Nitric oxide 
NT-3 = Neurotrophin-3 
PAMPs = Pathogen-associated molecular patterns 
PEA = Palmitoylethanolamide 
PI3K = Phosphatidylinositol3kinase 
PLOSL = Polycystic lipomembranous osteodysplasia 
with sclerosing leukoencephalopathy 
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PPAR = Peroxisome proliferator-activated receptor 
PRRs = Pattern recognition receptors 
PSR = Phosphatydilserine receptor 
ROS = Reactive oxygen species 
SAMPs = Self-associated molecular patterns 
SH2 = Src homology 2 
SHP1 = Tyrosine phosphatase 1 
SHP2 = Tyrosine phosphatase 2 
STAT-1 = Signal Transducers and Activators of Tran-
scription 1 
TGF = Transforming growth factor 
Th1 = Lymphocyte T helper 1  
Th2 = Lymphocyte T helper 2 
THC = 9-Tetrahydrocannabinol 
TLR = Toll like receptors 
TMEV-IDD = Theiler’s murine encephalomyelitis virus-
induced demyelinating disease 
TNF = Tumor necrosis factor alpha 
TREM-2 = Triggering receptor expressed on myeloid 
cells 2 
TREM-2L = Triggering receptor expressed on myeloid 
cells 2 ligand 
TRPV1 = Transient receptor potential vanilloid 1 
ZAP70 =  associated protein of 70kDa 
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